DRG Market Assessment 보고서

Last Updated 22 December 2014 Atrial fibrillation (AF) is the most common cardiac arrhythmia encountered in clinical practice. AF is a major cause of morbidity and mortality and is therefore a…

LaunchTrends: Keytruda (Wave 1) is the first in a series of syndicated reports designed to track physician perception, uptake, and competitive environment regarding the newly launched malignant…

The poor prognosis of advanced malignant melanoma (melanoma) patients means that there is a significant need for effective therapies to treat patients in this indication and a large commercial…

LaunchTrends: Keytruda (Wave 1) is the first in a series of syndicated reports designed to track physician perception, uptake, and competitive environment regarding the newly launched malignant…

Squamous cell carcinoma of the head and neck (SCCHN) is one of the six most frequently diagnosed malignancies worldwide. Second/third primary tumors are the main threats to long-term survival once…

This LaunchTrends report series will track the post-launch awareness, trial, and usage of Apremilast (Otezla) among rheumatologists for the treatment of Psoriatic Arthritis. Three waves of the…

Historically, developers of systemic lupus erythematosus (SLE) drugs faced formidable challenges: drug development and regulatory hurdles, a small and heterogeneous population, and a multiplicity…

Emerging markets present great opportunities but also numerous challenges to multinational pharmaceutical corporations (MNCs). With large and growing populations, robust projected market growth,…

Last Updated 16 December 2014 In late age-related macular degeneration (AMD), vision deficits are noticeable, often debilitating, and can be a precursor to blindness. The availability of vascular…

Last Updated 15 December 2014 Tumor necrosis factor (TNF)-α inhibitors continue to dominate the multibillion-dollar rheumatoid arthritis (RA) market. An increase in the prevalent RA population,…

According to the World Health Organization, cardiovascular disease (CVD) remains the number one cause of death globally. With the prevalence of CVD set to increase significantly over the next…

Last Updated 15 December 2014 Hospital-treated infections (HTIs) constitute a high-value segment of the antibacterial market owing to their severity, which drives the use of potent and branded…